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Abstract
The direct intratumoral (i.t.) injection of anticancer
agents has been evaluated extensively in the past few
decades. Thus far, however, it has failed to become
established as an alternative route of administration in
routine clinical practice. In the present report, the
impact of i.t. injection on the biodistribution and the
therapeutic potential of N-(2-hydroxypropyl)methacryl-
amide (HPMA) copolymer–based drug delivery sys-
tems was investigated. It was found that, compared to
intravenous injection, both the tumor concentrations
and the tumor-to-organ ratios of carriers improved
substantially. In addition, compared to intravenously
and intratumorally applied free doxorubicin and to
intravenously applied poly(HPMA)–glycylphenylalanyl-
leucylglycine–doxorubicin, intratumorally injected
poly(HPMA)–glycylphenylalanylleucylglycine–doxo-
rubicin presented a significantly increased antitumor
efficacy, as well as an improved therapeutic index.
Based on these findings, we propose intratumorally in-
jected carrier-based chemotherapy as an interesting al-
ternative to routinely used chemotherapy regimens and
routes of administration.
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Introduction
Even though the direct intratumoral (i.t.) injection of anti-
cancer agents has been evaluated extensively in the past
few decades [1–5], it has not been established as an alter-
native route of administration in routine clinical practice. This
is generally considered to be due to the invasive nature of
i.t. injection, the relatively rapid clearance of topically applied
drugs from tumors, and the development of dose-limiting
toxicities in tissues surrounding the site of application. In
addition, those types of tumors that would, in principle, be
readily accessible for i.t. injection are generally being treated
with more standardized (and more effective) locoregional treat-
ment modalities, such as surgery and radiotherapy.
Alongside advances in establishing novel antitumor thera-
peutics, a large number of drug delivery systems have been
developed over the years, both for parenteral and for topical
administration [6–10]. Thus far, however, even though several
highly innovative delivery systems have been designed spe-
cifically for locoregional application, only very few havemanaged
to progress into clinical trials. Taking this observation into ac-
count, we set out to evaluate the impact of i.t. injection on the
biodistribution and therapeutic potential of N-(2-hydroxypropyl)-
methacrylamide (HPMA) copolymer–based drug delivery sys-
tems.Copolymers ofHPMAareprototypic andwell-characterized
polymeric drug carriers that have been broadly implemented
in the delivery of anticancer therapeutics and that have been
tested in several phase I and phase II clinical trials [11–15].
In the first set of experiments, the circulation kinetics, organ
distribution, and tumor localization of intravenously and intra-
tumorally applied HPMA copolymers were investigated in rats
bearing subcutaneously transplanted Dunning AT1 tumors.
Subsequently, the impact of i.t. injection on the biodistribution
of poly(HPMA)–glycylphenylalanylleucylglycine (GFLG)–
doxorubicin was assessed to evaluate whether the effects
observed for chemically unmodified HPMA copolymers also
hold for a clinically relevant HPMA copolymer carrying a
chemotherapeutic drug. Finally, the antitumor efficacy, toxicity,
and therapeutic index of intravenously and intratumorally ap-
plied poly(HPMA)–GFLG–doxorubicin were analyzed, and
they were compared to those of intravenously and intratumor-
ally applied free doxorubicin.
Abbreviations: HPMA, N-(2-hydroxypropyl)methacrylamide; i.t., intratumoral; i.v., intravenous;
p.i., postinjection
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It was found that i.t. injection substantially improved both
the tumor concentrations and the tumor-to-organ ratios of
copolymers. In addition, compared to intravenously and intra-
tumorally applied free doxorubicin and to intravenously
applied poly(HPMA)–GFLG–doxorubicin, intratumorally
administered poly(HPMA)–GFLG–doxorubicin improved
both the efficacy and the toxicity of a single dose of chemo-
therapy. Based on these findings, we propose that—when
advanced solid malignancies are easily accessible (e.g.,
intraoperatively)—intratumorally administered carrier-based
chemotherapy be considered as an alternative to routinely
used chemotherapy regimens and routes of administration.
Materials and Methods
Chemicals
Methacryloyl chloride, methacrylic acid, 1-aminopropan-
2-ol, tyrosine amide, glycylglycine, glycylphenylalanine,
leucylglycine, 4-nitrophenol, dimethylsulfoxide (DMSO),
and doxorubicin hydrochloride were obtained from Fluka
(Prague, Czech Republic) and were of appropriate ana-
lytic grade.
Synthesis and Characterization of Copolymers
TheHPMAcopolymers used in this studywere synthesized
as described previously [16]. Briefly, poly(HPMA–co-MA-
TyrNH2) was prepared by the solution radical copolymerization
of the monomers HPMA and MA-TyrNH2 in methanol. The
weight-average molecular weight (Mw), number-average mo-
lecular weight (Mn), and polydispersity (Mw/Mn) of copolymers
after their fractionation (on Superose 4B/6B columns, Amer-
sham Biosciences, Prague, Czech Republic) were deter-
mined by size exclusion chromatography on an A¨kta
Explorer (Amersham Biosciences) equipped with UV–VIS,
a differential refractometer (Shodex R-72, Kawasaki, Japan),
and a multiangle light scattering detector (DAWN DSP-F;
Wyatt Technology Corp., Santa Barbara, CA). The average
molecular weights of the two parental HPMA copolymers
were 30.5 and 64.5 kDa, respectively; their polydispersities
were 1.3 and 1.2, respectively; and the relative amounts of
tyrosine amide, included to allow for radiolabeling, were
0.8 and 0.3 mol%, respectively.
The precursor for poly(HPMA)–GFLG–doxorubicin [i.e.,
poly(HPMA)–co-MA-TyrNH2–co-MA-Gly-DL-PheLeuGly-
ONp] was prepared by the precipitation radical terpoly-
merization of HPMA, MA-TyrNH2, and MA-GFLG-ONp in
acetone. After purification, doxorubicin was conjugated to
the precursor in DMSO, in the presence of Et3N. The reaction
mixture was stirred for 4 hours, 1-aminopropan-2-ol was
added, and the mixture was precipitated into a mixture
of acetone/diethylether (3:1). The resulting doxorubicin-
containing conjugate was then filtered off, dried in vacuum,
purified on a Sephadex LH-20 column (Sigma-Aldrich,
Prague, Czech Republic) (to remove free doxorubicin), and
purified on a Sephadex LH-60 column (Sigma-Aldrich)
(to obtain a narrow distribution of molecular weights). The
molecular weight of the conjugate was 27.9 kDa, its poly-
dispersity was 1.5, the amount of MA-TyrNH2 was 1.3 mol%,
and the amount of doxorubicin was 6.5 wt.%.
Radiolabeling
Iodine-131 (131I) was obtained from Amersham (Freiburg,
Germany). The tyrosine amide groups incorporated into
copolymers were radiolabeled using the mild oxidizing agent
1,3,4,6-tetrachloro-3a,6a-diphenyl glycoluril (i.e., Iodogen
[17]). On 10 minutes of incubation, the mixture of 131I,
Iodogen, and copolymer was applied to a Biogel-P6 column
(Bio-Rad Laboratories, Mu¨nchen, Germany) and eluted with
30 ml of phosphate-buffered saline. The eluate was re-
covered in 1-ml fractions, and the radioactivity of each of
these fractions was determined by a scintillation counter.
The radiolabeled copolymer was retrieved in the fifth to the
seventh milliliter of the eluate, whereas free (i.e. inbound)
131I was eluted in the fourteenth to the eighteenth milli-
liter. As this methodology allowed us to concentrate the
copolymer-associated fraction, no additional purification
was required. The efficacy of radiolabeling was quantified
by dividing the amount of radioactivity collected in the fifth to
the seventh milliliter of the eluate by the total amount of
radioactivity retrieved (i.e., by the sum of the activities
detected in all thirty 1-ml fractions). The labeling efficacies
for 31-kDa poly(HPMA), 65-kDa poly(HPMA), and 28-kDa
poly(HPMA)–GFLG–doxorubicin were 95.2%, 96.2%, and
86.3%, respectively.
Animal Model
All experiments involving animals were approved by an
external committee for animal welfare and were performed
according to the guidelines for laboratory animals established
by the German Government. Experiments were performed
on 6- to 12-month-old male Copenhagen rats (Charles River
WIGA, Sulzfeld, Germany) using the syngeneic Dunning
R3327-AT1 prostate carcinoma model [18]. Throughout the
experimental procedure, the animals were anesthetized
with Ethrane (DeltaSelect, Pfullingen, Germany). Fresh
pieces of AT1 tumor tissue (c 10 mm3) were prepared from
an AT1 donor tumor and were transplanted subcutaneously
into the right hindlimbs of the rats. Tumors were grown for
12 to 18 days until they had reached an average diameter
of 12 mm.
Biodistribution
To analyze the biodistribution of the copolymers on intra-
venous (i.v.) injection, 500 ml of a saline solution containing
0.1 mmol of HPMA copolymer (based on copolymer concen-
tration and corresponding to a radioactivity of 150–300 mCi)
was injected intravenously into the lateral tail vein of the
animals. The biodistribution of the copolymers on i.t. injection
was evaluated by administering a substantially smaller vol-
ume (50–100 ml) containing the same amount of copolymer
(i.e., 0.1 mmol; 150–300 mCi) directly into the center of the
tumors. Immediately after i.t. injection, the application site
was covered and washed twice with absorbing paper to
retrieve the radiolabeled copolymer leaking out of the tumor.
At 0.1, 0.25, 1, 4, and 24 hours postinjection (p.i.), the
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concentrations of the copolymers in systemic circulation were
determined by withdrawing 50 ml of blood from the tail vein
of the rats and by assuming that the complete blood pool
equals 6% of their body weight. At 0.5, 4, and 24 hours
p.i., the biodistribution of the copolymers was monitored
two-dimensionally using a Searle-Siemens (Erlangen, Ger-
many) scintillation camera. At 24 hours p.i., the animals were
sacrificed, and their tumors and organs were harvested for
quantification. The residual amounts of radioactivity were
determined using a gamma counter, corrected for radioactive
decay, and expressed as percentage of injected dose per
gram of tissue (% ID/g).
In Vitro Efficacy
The cytotoxicity of free and HPMA copolymer–bound
doxorubicin was determined by seeding 200 Dunning AT1
cells into six-well plates. Four hours later, the cells were
treated with 0.001 to 10 mmol of free doxorubicin, 0.001
to 1000 mmol of poly(HPMA)–GFLG–doxorubicin, and
0.001 to 1000 mmol of a drug-free control copolymer. After
8 to 10 days, the cells were fixed and stained with crystal
violet, and the number of surviving colonies was counted.
Antitumor Efficacy
Rats bearing 10- to 15-mm AT1 tumors were randomly
assigned to various treatment groups. Free and HPMA
copolymer–bound doxorubicin were administered by a single
i.v. or i.t injection at a (doxorubicin-equivalent) dose of
5 mg/kg. Tumor volumes were calculated using the for-
mula: V = [a(bb)]/2, where a is the largest diameter and b is
the smallest diameter, and they were expressed relative to
the tumor volume determined on the first day of therapy. The
toxicity of the four regimens was assessed by measuring
the relative body weight (loss) of the animals.
Statistical Analysis
All values are expressed as average ± SD. In the experi-
ments addressing the kinetics, biodistribution, and tumor
localization of the copolymers, the standard Student’s t test
was used. In the experiments evaluating the efficacy and the
toxicity of the various treatment regimens, the Mann-Whitney
U test was used. In both cases, P < .05 was considered
statistically significant.
Results
Effect of i.t. Injection on the Kinetics of HPMA Copolymers
First, the impact of i.t. injection on the circulation kinetics
of two chemically unmodified HPMA copolymers (i.e., with-
out spacer and drug) was investigated. Hereto, 31-kDa
and 65-kDa poly(HPMA) were radiolabeled and adminis-
tered to the rats either as an i.v. bolus injection or directly
into the center of the tumors. Figure 1A shows that, up to
24 hours p.i., the blood concentrations of intratumorally
applied 31-kDa poly(HPMA) were significantly lower than
those of intravenously applied 31-kDa poly(HPMA). At 1 and
24 hours p.i., for instance, 30.1 ± 5.2% and 4.9 ± 0.7%
ID were found in blood on i.t. administration, compared to
67.4 ± 3.3% ID (P < .0001) and 11.2 ± 0.7% ID (P < .0001)
on i.v. administration.
Figure 1B shows that, also for 65-kDa poly(HPMA), the
levels in the systemic circulation were significantly lower on
i.t. injection. At 1 and 24 hours p.i., 17.2 ± 11.6% and 20.5 ±
3.7% ID were found on i.t. administration vs 78.8 ± 3.4%
ID (P < .0001) and 24.0 ± 0.8% ID (P < .05) on i.v. adminis-
tration, respectively. Compared to 31-kDa poly(HPMA), a
different pharmacokinetic pattern was observed for 65-kDa
poly(HPMA). For the smaller copolymer, the concentrations
in blood were found to be relatively high immediately on
i.t. injection (f50% ID at 5 minutes p.i.) and gradually
decreased over time. For the larger copolymer, however,
the initial levels were relatively low (f10% ID at 5 minutes
p.i.) and they tended to remain constant over time. This
indicates that larger HPMA copolymers are retained in tumor
more effectively than smaller HPMA copolymers.
Effect of i.t. Injection on the Biodistribution of HPMA
Copolymers
Next, the tumor localization and organ distribution of
intravenously and intratumorally applied HPMA copolymers
were compared. As shown in the scintigrams in Figure 2A, at
Figure 1. Effect of i.t. injection on the circulation kinetics of HPMA copolymers. The blood concentrations of 31-kDa poly(HPMA) (A) and 65-kDa poly(HPMA)
(B) after i.v. and i.t. injection are plotted against time. Values represent the average ± SD of four to six animals per experimental group. *P < .0001 vs i.v. injection.
#P < .05 vs i.v. injection (Student’s t test).
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4 and 24 hours after i.v. injection, alongside a substantial
accumulation in AT1-sc tumors, significant amounts of the
copolymers were also found in the heart (i.e., circulation),
spleen, and liver. On i.t. application, however, only localiza-
tion to the tumors could be observed over the first 24 hours
after administration (Figure 2A).
In addition, the scintigrams in Figure 2A point toward an
accumulation of radioactivity in the thyroid. This, however, is
due to the release of 131I from copolymers; under physio-
logical conditions, a small amount of radiolabel is liberated
from incorporated tyrosine amide groups (approximately 2%
per 24 hours). Most of this released 131I is eliminated rapidly
by renal filtration; a significant portion, however, is always
taken up by thyroid cells, as these cells specifically express
the sodium–iodine symporter.
At 24 hours p.i., the tumors and organs were then har-
vested, and the concentrations of the copolymers were
quantified. Figure 2, B and C, shows that, on i.v. injection,
the highest amounts of the copolymers were always detected
in the spleen, followed by the lungs and tumor. For 31-kDa
poly(HPMA), the levels localizing to the tumor were 0.38 ±
0.03% ID/g for i.v. injection and 1.42 ± 0.52% ID/g for i.t.
injection (P = .0023). In the spleen, lungs, and liver, the con-
centrations of intravenously applied 31-kDa poly(HPMA)
were 0.52 ± 0.04%, 0.39 ± 0.06%, and 0.19 ± 0.03% ID/g,
respectively, compared to 0.38 ± 0.06%, 0.26 ± 0.04%, and
0.15 ± 0.04% ID/g, respectively, for intratumorally applied
31-kDa poly(HPMA). These findings indicate that, in addition
to increasing the tumor concentrations of this copolymer, i.t.
injection also decreases its localization to healthy tissues.
Overall, however, the differences were less obvious than
predicted by the scintigrams, and they were only found to
be significant for the spleen (P = .0043), lungs (P = .0039),
and heart (P = .0026).
For 65-kDa poly(HPMA), an identical biodistributional
pattern was observed. As shown in Figure 2C, 24 hours after
Figure 2. Effect of i.t. injection on the biodistribution of HPMA copolymers. (A) Scintigraphic analysis of the effect of i.t. injection on the biodistribution of 31-kDa and
65-kDa poly(HPMA) in rats bearing subcutaneously transplanted AT1 tumors. In the images obtained 0.5 hour after i.v. administration, the accumulation of the
radiolabeled copolymers was most prominent in the heart (i.e., circulation) (1) and bladder (2). In the images obtained at 4 and 24 hours, the highest amounts of the
copolymers were found in the heart/lungs (1), spleen (3), liver (4), and tumor (5). In addition, at the two latter time points, released radioactive iodine was found to
accumulate in the thyroid (T). On i.t. injection, only localization to the tumor (5) could be observed over the first 24 hours after administration. (B and C)
Quantification of the effect of i.t. injection on the tumor and organ concentrations of 31-kDa poly(HPMA) (B) and 65 kDa-poly(HPMA) (C) at 24 hours p.i. Values
represent the average ± SD of four to six animals per experimental group. *P < .05 vs i.v. injection (Student’s t test).
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i.v. injection, the highest concentrations of the copolymer
were found in the spleen (1.67 ± 0.06% ID/g), lungs (1.06 ±
0.15% ID/g), tumor (0.87 ± 0.06% ID/g), and liver (0.80 ±
0.05% ID/g). On i.t. injection, its levels in these tissues were
1.12 ± 0.37% ID/g (P = .0059), 0.86 ± 0.35% ID/g (P = .2314),
11.9 ± 9.5% ID/g (P = .0195), and 0.66 ± 0.19% ID/g
(P = .0971), respectively. Thus, as for 31-kDa poly(HPMA),
i.t. injection not only increased the tumor accumulation of
65-kDa poly(HPMA) but also attenuated its localization to
several healthy tissues.
To more directly assess the effects of i.t. injection on the
biodistribution of the copolymers, tumor-to-organ ratios were
calculated. Hereto, the tumor concentrations of 31-kDa and
65-kDa poly(HPMA) at 24 hours p.i. were divided by the
respective organ concentrations at 24 hours p.i. As shown
in Table 1, the tumor-to-organ ratios of intratumorally applied
31-kDa poly(HPMA) were, on average, four-fold higher than
those of intravenously applied 31-kDa poly(HPMA). For
65-kDa poly(HPMA), i.t. injection improved the tumor-to-
organ ratios by a factor 15 to 20. These findings indicate that
the (positive) impact of i.t. injection correlates with the mo-
lecular weight of copolymers.
Effect of i.t. Injection on the Biodistribution
of Poly(HPMA)–GFLG–Doxorubicin
To evaluate whether the effects observed for the two
chemically unmodified copolymers also hold for a clinically
relevant HPMAcopolymer carrying a chemotherapeutic drug,
we also analyzed the impact of i.t. injection on the bio-
distribution of poly(HPMA)–GFLG–doxorubicin. As shown
in the scintigrams in Figure 3A, the biodistribution of intra-
venously applied poly(HPMA)–GFLG–doxorubicin seems to
be very different from that observed for the two parental
copolymers (Figure 2A). In a previous study, however, we
have shown that, as a result of the incorporation of drug
and/or spacer moieties, the kidney concentrations of the
copolymers are always induced significantly (f 5- to 10-fold),
whereas their relative levels in the majority of other tis-
sues are affected only moderately [16]. The scintigrams in
Table 1. Summary of the Effects of i.t. Injection on the Biodistribution and
Therapeutic Potential of HPMA Copolymer–Based Drug Delivery Systems:
Evaluation of the Tumor-to-Organ Ratios of Intravenously and Intratumorally
Applied HPMA Copolymers.
31-kDa
poly(HPMA)
65-kDa
poly(HPMA)
28-kDa poly(HPMA)–
GFLG–Doxorubicin
i.v. i.t. i.v. i.t. i.v. i.t.
Tumor 1 1 1 1 1 1
Spleen 0.7 3.8 0.5 10.6 0.2 1.9
Lungs 1.0 5.5 0.8 13.8 1.2 8.5
Liver 2.0 9.4 1.1 18.0 1.3 8.1
Kidneys 1.6 6.3 1.3 18.1 0.1 0.5
Heart 3.2 14.1 1.5 24.6 3.2 15.6
Testes 2.8 13.7 1.7 32.0 2.8 14.8
Skin 5.0 19.7 3.5 49.0 1.6 9.4
Ileum 3.5 13.6 3.3 40.3 2.5 19.3
Muscle 12.0 36.6 6.2 120.7 7.6 45.7
Tumor-to-organ ratios were calculated 24 hours after i.v. and i.t. in-
jection. Hereto, the tumor concentrations of 31-kDa poly(HPMA), 65-kDa
poly(HPMA), and 28-kDa poly(HPMA)–GFLG–doxorubicin at 24 hours
p.i. were divided by the respective organ concentrations at 24 hours p.i. A
tumor-to-organ ratio of >1 indicates a preferred localization to tumor tis-
sues; a ratio of <1 indicates a more selective localization to the corresponding
healthy tissues. The tumor-to-organ ratios allow for a more direct evaluation
of the impact of i.t. injection on the biodistribution of the copolymers.
Figure 3. Effect of i.t. injection on the biodistribution of poly(HPMA)–GFLG–doxorubicin. (A) Scintigraphic analysis of the effect of i.t. injection on the
biodistribution of poly(HPMA)–GFLG–doxorubicin (PK1) in rats bearing subcutaneously transplanted AT1 tumors. In the images obtained 0.5 hour after i.v.
injection, the accumulation of the radiolabeled conjugate was most prominent in the heart (i.e., circulation) (1) and bladder (2). At 4 and 24 hours, most of the
conjugate was found in the kidneys (3) and tumor (4). Released radioactive iodine was again found to accumulate in the thyroid (T). On i.t. injection, the highest
amounts of poly(HPMA)–GFLG–doxorubicin were found in the kidneys (3) and tumor (4). (B) Quantification of the effect of i.t. injection on the tumor and organ
concentrations of poly(HPMA)–GFLG–doxorubicin (PK1) at 24 hours p.i. Values represent the average ± SD of three to four animals per experimental group. *P <
.05 vs i.v. injection (Student’s t test).
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Figure 3A furthermore exemplify that, as for the two parental
HPMA copolymers, i.t. injection substantially improved the
tumor localization of poly(HPMA)–GFLG–doxorubicin.
Quantification at 24 hours p.i. confirmed this notion, showing
that 2.00 ± 0.28% ID/g was found for i.t. administration,
compared to 0.36 ± 0.02% ID/g (P = .0006) for i.v. adminis-
tration (Figure 3B). Figure 3B also shows that i.t. injection
reduced the amount of poly(HPMA)–GFLG–doxorubicin
accumulating in the spleen (P = .0018), kidneys (P =
.0261), and skin (P = .0091). As a result, the tumor-to-organ
ratios of intratumorally applied poly(HPMA)–GFLG–doxo-
rubicin were found to be substantially higher than those of
intravenously applied poly(HPMA)–GFLG–doxorubicin; on
average, they improved by more than 500% (Table 1).
In Vitro Efficacy of Free and HPMA Copolymer–Bound
Doxorubicin
Subsequently, the cytotoxicity of poly(HPMA)–GFLG–
doxorubicin was compared to that of free doxorubicin. As
shown in Figure 4, free doxorubicin was found to be signifi-
cantly more effective than poly(HPMA)–GFLG–doxorubicin
in inhibiting the clonogenic survival of AT1cells. In linewith the
literature [19,20], the IC50 value of the free drug (f 0.3 mmol)
was approximately 100-fold lower than that of the copolymer-
bound drug (f 30 mmol). For a drug-free control copolymer,
no cytotoxic effects were observed.
Effect of i.t. Injection on the Efficacy and Toxicity of Free
and HPMA Copolymer–Bound Doxorubicin
Finally, the therapeutic efficacy of intravenously and intra-
tumorally applied poly(HPMA)–GFLG–doxorubicin (PK1)
was compared to that of intravenously and intratumorally
applied free doxorubicin. As shown in Figure 5A, neither a
single i.v. injection of free doxorubicin nor a single i.v. injection
of PK1 was able to inhibit the growth of aggressively growing
and relatively chemoresistant Dunning AT1 tumors. When
free doxorubicin was applied directly into the tumors, it was
only found to be significantly more effective than control
(P = .02). Intratumorally applied PK1, however, was not only
found to be more effective than control (P = .004) but also
found to be more effective than intravenously applied free
doxorubicin (P = .005), intratumorally applied free doxo-
rubicin (P = .03), and intravenously applied PK1 (P = .008).
In addition to evaluating the effect of i.t. injection on the
antitumor efficacy of free and HPMA copolymer–bound
doxorubicin, we also investigated its impact on the toxicity
of the two chemotherapeutic agents. Hereto, the body weight
(loss) of the animals was monitored throughout the course of
the experiment. As shown in Figure 5B, intravenously and
intratumorally applied PK1 turned out to be better tolerated
than intravenously and intratumorally applied free doxo-
rubicin; although the toxicity resulting from the two regimens
involving PK1 was comparable to that of control, both regi-
mens involving free doxorubicin were found to be significantly
more toxic than control (P = .01).
To more directly compare the overall therapeutic potential
of intravenously and intratumorally applied PK1 to that of
intravenously and intratumorally applied free doxorubicin,
therapeutic indices were attributed to the four chemotherapy
Figure 4. In vitro efficacy of free and HPMA copolymer –bound doxorubicin.
The cytotoxicity of free doxorubicin, poly(HPMA)–GFLG–doxorubicin, and
control copolymer (lacking doxorubicin) was assessed by investigating the
ability of agents to inhibit the colony formation of AT1 rat prostate carcinoma
cells. Values represent the average ± SD of three independent experiments.
Figure 5. Effect of i.t. injection on the efficacy and toxicity of free and HPMA copolymer–bound doxorubicin. (A) Growth inhibition of subcutaneous AT1 tumors
induced by a single i.v. injection of saline (Control; n = 12), a single i.v. injection of 5 mg/kg free doxorubicin (Dox i.v.; n = 9), a single i.t. injection of 5 mg/kg
doxorubicin (Dox i.t.; n = 4), a single i.v. injection of 5 mg/kg (doxorubicin-equivalent) poly(HPMA)–GFLG–doxorubicin (PK1 i.v.; n = 7), and a single i.t. injection of
5 mg/kg (doxorubicin-equivalent) poly(HPMA)–GFLG–doxorubicin (PK1 i.t.; n = 4). *P < .05 vs control. #P < .005 vs control. yP < .01 vs Dox i.v. zP < .01 vs PK1 i.t.
§P < .05 vs DOX i.t. (Mann-Whitney U test). (B) Weight loss induced by the four chemotherapy regimens mentioned above. *P < .05 vs control and PK1 i.v. (Mann-
Whitney U test).
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regimens. Hereto, the relative increases in efficacy (i.e., in
tumor growth inhibition; compared to control) were divided by
the relative increases in toxicity (i.e., in body weight loss;
compared to control). On day 10 p.i., for instance, the relative
tumor volumes for control and intratumorally applied PK1were
417% and 238%, respectively (Figure 5A). The relative body
weights for these two regimens at this time point were 102%
and 100%, respectively (Figure 5B). The resulting therapeutic
index for intratumorally applied PK1 on day 10 is thus 1.72
[i.e., (417/238) / (102/100)]. As shown in Table 2, when si-
multaneously addressing the efficacy and the toxicity of
a single dose of chemotherapy, intratumorally applied PK1
turned out to be the most optimal regimen for treating Copen-
hagen rats carrying chemoresistant AT1 tumors; throughout
follow-up, its therapeutic indices were always well above 1
(i.e., better than those of saline controls) and they were also
always substantially higher than thosedetermined for the other
three chemotherapy regimens.
Discussion
Besides being the standard route of administration for most
(pre)clinical gene therapy applications [21 22], i.t. injection
has also been evaluated relatively extensively for improv-
ing the therapeutic index of standard anticancer agents
[1–5,23–25]. The obvious rationale behind this approach is
that the topical administration of chemotherapeutic drugs
increases the concentrations of agents at the target site,
while lowering their localization to healthy tissues. As a result,
i.t. injection is generally considered to improve the antitumor
efficacy of agents, while lowering the incidence and the
intensity of their side effects.
In principle, the rationale behind the implementation of
drug delivery systems is identical to that of i.t. injection: to
improve the therapeutic index of chemotherapeutic agents by
increasing their tumor concentrations and by decreasing their
accumulation in healthy tissues [6–10]. It therefore seems
logical that the combination of these two approaches (i.e.
the i.t. injection of drug delivery systems) holds significant
potential for further enhancing the efficacy of anticancer ther-
apy. Thus far, however, this combination has been largely
neglected, and only very few reports have evaluated the
impact of i.t. injection on the biodistribution and therapeutic
index of carrier-based chemotherapeutics. Those reports that
did investigate the efficacy of the combination have convinc-
ingly confirmed its potential; carmustine-containing polymeric
wafers designed specifically for (intraoperative) intracerebral
administration, for instance, have been shown to substantially
improve both the efficacy and the tolerability of chemotherapy,
and, consequently, they have been approved by the Food and
DrugAdministration for the treatment of glioblastoma [26–28].
Surely, drug delivery systems designed specifically for
topical administration can be expected to be more suitable
for i.t. administration than are delivery systems designed for
parenteral administration (e.g., HPMA copolymers). Based
on the notion, however, that HPMA copolymers are clinically
relevant drug carriers and that they are known to display
proper biocompatibility and enhanced tumor retention [8,
11–16], we decided to use HPMA copolymers to demon-
strate that, even by implementing drug delivery systems that
were designed specifically for parenteral administration, the
therapeutic index of locoregionally applied chemotherapy
can be improved substantially. On one hand, this was per-
formed to urge oncologists considering intraoperative or
postoperative chemotherapy to use carrier-based chemo-
therapeutics instead of standard chemotherapeutics. On the
other hand, this should also serve as a starting point and as
a rationale for intensifying the evaluation of drug delivery
systems designed specifically for topical administration.
In the present report, several lines of evidence indicating
that the implementation of drug delivery systems is indeed
a promising approach for improving the efficacy of loco-
regionally applied anticancer therapy are provided. First,
the blood concentrations of intratumorally injected drug de-
livery systems were found to be significantly lower than
those of intravenously injected delivery systems. This indi-
cates that the systemic toxicity of intratumorally applied
(carrier-based) chemotherapy can be expected to be lower
than that of intravenously applied (carrier-based) chemo-
therapy. Second, in line with the experimental evidence
provided by Harrington et al. [29], who showed that the
i.t. administration of colloidal drug carriers substantially
increases their tumor concentrations, we found that i.t. injec-
tion also substantially improves the biodistribution of poly-
meric drug delivery systems (Figures 2 and 3). Compared
to i.v. injection, the tumor-to-organ ratios resulting from i.t.
injection increased by up to 2000% (Table 1). Third, most
likely as a direct result of this improved tumor localization,
the antitumor efficacy of intratumorally applied poly(HPMA)–
GFLG–doxorubicin was found to be significantly higher
than that of intravenously applied poly(HPMA)–GFLG–
doxorubicin and intravenously and intratumorally applied
free doxorubicin (Figure 5A). At the same time, the toxicity
of this regimen turned out to be attenuated (Figure 5B),
resulting in a substantial improvement in the overall thera-
peutic index of the intervention (Table 2). These findings
indicate that when advanced solid malignancies are easily
Table 2. Summary of the Effects of i.t. Injection on the Biodistribution and
Therapeutic Potential of HPMA Copolymer–Based Drug Delivery Systems:
Analysis of the Therapeutic Index of Intravenously and Intratumorally Applied
Free and HPMA Copolymer–Bound Doxorubicin.
Time (days)
1 3 6 8 10 13 15 17 20
Control 1 1 1 1 1 1 1 1 1
Dox i.v. 1 1.12 1.09 1.14 1.06 1.07 1.07 1.00 1.00
Dox i.t. 1 1.00 1.19 1.30 1.56 1.50 1.58 1.59 1.56
PK1 i.v. 1 0.95 0.97 1.06 1.13 1.14 1.12 1.06 1.08
PK1 i.t. 1 1.17 1.24 1.37 1.72 1.55 1.67 1.85 2.13
Therapeutic indices were determined for each of the four chemotherapy
regimens throughout the course of the experiment. To quantify therapeutic
indices, relative increases in efficacy (i.e., in tumor growth inhibition;
compared to saline control) were divided by relative increases in toxicity
(i.e., in body weight loss; compared to saline control; see text for details). The
assessment of therapeutic indices is intended to allow for a more direct and
cross-sectional comparison of the overall therapeutic potential of the four
chemotherapy regimens.
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accessible (e.g., intraoperatively), the i.t. injection of HPMA
copolymer–based chemotherapeutics—and likely of all
carrier-based chemotherapeutics—should be considered
as an interesting alternative to routinely used chemotherapy
regimens and routes of administration.
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